Breaking News
Investing Pro 0
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER

AdAlta research collaborators publish paper suggesting use for i-body as therapy for osteoporosis

Stock Markets Jan 25, 2023 12:30
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. AdAlta research collaborators publish paper suggesting use for i-body as therapy for osteoporosis
 
IX
-5.17%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

AdAlta Ltd (ASX:1AD) says a new publication by its collaborators at University of Western Australia (UWA) and La Trobe University, published in the peer reviewed Journal of Biological Chemistry, suggests the potential for i-bodies as therapies for osteoporosis.

The clinical-stage biotechnology company, which is developing novel therapeutic products from its i-body platform says the publication further demonstrates the broad applicability of the i-body platform and opens up another area of commercial potential.

The work is the subject of a patent application.

Potential use for i-bodies

The research, led by Prof Jiake Xu at UWA, suggests the potential to use i-bodies as improved therapies for osteoporosis and other bone diseases.

Bone resorption is controlled by a cell membrane protein called RANKL.

The published data demonstrate that an i-body, ADR3, that binds to RANKL can inhibit a wide range of cell signalling pathways controlled by RANKL, reducing bone resorption in in-vitro assays.

ADR3 demonstrated stability properties suitable for a therapeutic agent.

AdAlta CEO and managing director Dr Tim Oldham said: “This work further demonstrates the potential of the i-body platform to engage diverse targets to modify disease.

“We look forward to continuing to support Professor Xu and his team as they work to discover improved therapies for osteoporosis.

“We have applied for a patent to protect this invention and are open to industry collaborations to advance this program.”

Huge US market

Osteoporosis is the result of imbalance between bone forming and bone resorption processes resulting in reduced bone density and the increased risk of fractures, particularly of the hip, spine and wrist.

In the US, EU and Japan it affects 20% of women and 5% of men aged over 50 and costs the US healthcare system more than US$25 billion per year.

Therapeutics to treat osteoporosis and reduce fracture risk generate sales of US$8 billion per year, with the leading antibody product, Prolia™ (denosumab) generating US$3.2 billion.

Side effects such as osteonecrosis of the jaw (breakdown of the jaw bone), severe hypocalcaemia (low calcium levels) and increased femur (thigh) fractures may prompt the need for the discontinuation of therapy, which in turn causes a rebound of increased bone resorption and an increased risk of fractures.

There is therefore a need for improved therapies for osteoporosis.

Read more on Proactive Investors AU

Disclaimer

AdAlta research collaborators publish paper suggesting use for i-body as therapy for osteoporosis
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email